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Net Histocompatibility Ratios (NHR) for Clinical 
Transplantation 
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G. ANDRES, 1. PENN, C. W. PUTNAM AND T. E. STARZL 
IN THIS STUDY, the histocompatibility 
match of a group of patients treated at least 
one and a half years ago was calculated by 
a modification of the net histocompatibility 
ratio (NHR) formula of Rapaport and 
Dausset. 1 Correlations were then made with 
the outcome as judged by patient and kid-
ney survival, homograft function, the mag-
nitude of maintenance immunosuppression, 
and the extent of histopathologic abnormal-
ities in the transplants. 
MATERIALS AND METHODS 
The cases were those recently reported in detail2 
and started with unculled groups of 131 consecu-
tive recipients whose first kidneys were given by 
blood relatives and of 58 consecutive recipients 
of nonrelated kidneys (35 volunteers and 23 
cadavers). The related cases were compiled 2J1.-
7% years ago and the nonrelated cases from 
lJ1.-7J. years ago. The immunosuppression for 112 
of the patients was azathioprine and prednisone; 
the last 77 were also given heterologous AI,G. 
Of the 189 cases, all were included if the raw 
lymphocyte antigen typing uata were available for 
both donor and recipient. There was sufficient 
information with transplantations from 56 siblings, 
49 parents, 8 more distant rdatives (aunts, uncles, 
and cousins which were included for the various 
statistical analyses with the siblings) and 38 non-
relatives (total 151). Correlations of match with 
survival were made in all 151 typed cases. For 
the related recipients, matches were correlated 
with steroid dosage and homograft function at 1 
and 2 years in thc event of survival for these 
periods; the same applied in nonrelated cases 
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except that survival periods for sampling were 1 
and llf years. 
Correlations of the matches expressed by the 
NHR with histopathology were done only if the 
homografts sampled had been in residence for at 
least 2* months, thereby excluding 8 of the 151 
cases because of death before this timc. Twenty-
one specimens included in the analysis were ob-
tained at autopsy or at homograft nephrectomy 
from 21f to 27 months after transplantation. Most of 
the tissues studied (113 total) were biopsies taken 
after 15-33 months. Nine of the homografts have 
never become available under any of the foregoing 
circumstances. The tissues were examined with 
light microscopy, and in most instances by electron 
microscopy and immunofluorescence (IF) as de-
scribed elsewhereK~ Insofar as the method of tissue 
collection permitted, the presence or absence of 
the 13 features listed in Table 2 were determined 
and graded in severity from 0 to 4. 
The NHR calculation1 was based upon the 
hypotheses that the major histocompatibility fac-
tors are on two loci of a single (HL-A) chro-
mosome, that each locus governs the expression 
of two histocompatibility antigens, and that the 
measurement of either more or less than two anti-
gens at one or the other locus is by definition 
probably a methodologic artifact. In the formula, 
NHR = 14 (donor-recipient antigen identities/ 
antigen incompatibilities), adjustments were made 
by the deSignation of "potential relations" if a full 
complement of alleles could not be defined in 
either the donor or recipient, particularly the 
former. The result was to depreciate the NHR 
value in situations with transplantation of no anti-
gen to antigen by conSidering this as a "potential" 
rather than as an identity and by therefore pre-
venting it from contributing to a high NHR score. 
A second adjustment was to consider the following 
three families of cross reacting antigens to be 
operationally identical": HL-A 1 (HL-A 3 if pres-
ent as a third antigen); HL-A 5 (Te 6, Te 55, 
~aata on cross reacting antigens were developed 
at the workshops of the Fourth Histocompatibility 
Conference convened in Los Angeles, January 24-
26, 1970. 
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Te 58); and HL-A 7 (Te 51, Te 60). This latter 
adjustment tended to improve the NHR scores by 
changing a number of incompatibilities to com-
patibilities; in no instance was the NHR worsened. 
In some cases in which typing was carried out 
several years ago with a mllltispecific antiserum 
called "Old 3," a positive reaction could have been 
due to HL-A 9 or HL-A 10 on the first sublocus 
or HL-A 5, HL-A 12, or Te 60 on the second 
sllblocus. The interpretation of the "Old 3" reac-
tions was on a highly individual basis. All KHR 
scores were computed by Rapaport" without 
knowledge of the outcome in the cases under 
scrutiny. To those monitoring these calculations, 
it was obvious that an element of judgment and 
intelligence was introduced which rendered the 
determinations much more than a technical exer-
cise, and which would make difficult a duplication 
of the scores by the simple insertion of data into a 
strict mathematical formula. 
RESULTS 
Survival 
Cumulative proportional survivals were 
calculated by the life table method de-
veloped for cancer statistics by Cutler and 
Ederer.3 The recipients of related kidneys 
were at potential risk for 31-92 months 
post-transplantation. In the sibling cases 
and in the parent to offspring transplanta-
tions (Fig. 1), the three patient groups de-
fined with NHR scores did not belong to 
significantly different populations at any 
stage of followup as judged by Mantel's 
Chi-square procedures4 for comparing two 
sets of life table data in their entirety. 
The same general conclusions applied 
with the series of nonrelated transplanta-
tions in which complete potential followup 
of 38 typed recipients was available out to 
18 months with maximum followups of as 
long as 78 months. Long after operation (in 
the third to sixth postoperative years) there 
seemed to be an advantage of a good NHH. 
score (Fig. 1) but with the Chi-square 
procedure mentioned above this never ap-
proached statistical significance. The maxi-
mum Chi-square value of 1.28 was at 75 
months; significance would have required 
a figure of 3.84 or greater. It was of interest 
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Fig. I.-Cumulative proportional survival 
curves of recipients of related and unrelated 
renal homografts, divided according to the net 
histocompatibility ratio (NHR) scores. The 
minimum followup for each curve is indicated 
by an arrow (see text for details). 
that all the patients with an NHR score 
> 0.5 were operated upon 57 months or 
longer ago. The donors in these cases were 
not available for retyping, making it neces-
sary to compute the NHR values with rela-
tively fragmentary serologic data and with 
a consequent need for guess work. Thus, a 
form of inadvertent bias may have been 
introduced of the kind that could ultimately 
have affected other statistical analyses such 
as those of pathologic abnormalities (see 
below). 
Function and Immunosuppression 
In the sibling, parent, and nonrelated 
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Table l.-NHR vs. Function and Immunosuppression in 124 Renal Transplantations 
----
---------- ---
Average Creatinine Average BUN t Average Prednisone 
Dosage t Clearance t 
No. of ("c. min.) ( mg. per cent) (mg./Kg./day) 
1 Yr. 2 Yr. NHR Patients" 1 Yr. 2Yr. 1 Yr. 2 Yr. 
-~ - --------- -----------
Siblings t >0.5 24 (22) 84 87 23 25 0.20 0.21 
0.5 27 (24) 84 84 28 23 0.27 0.18 
< 0.5 8 92 71 26 28 0.24 0.21 
Parentals >0.5 14 69 67 27 26 0.32 0.25 
0.5 24 (2.2) 72 71 24 28 0.23 0.18 
< 0.5 3 58 80 45 42 0.44 0.19 
Unrelated ;:::: 0.5 ll( 9) 79 64 25 27 0.38 0.36 
<0.5 13 67 61 40 30 0.40 0.31 
-----------
., In parenthesis is the number of patients available for analysis at 2 years in related and at r~ years 
in unrelated cases if different than that of one year. 
t Averages calculated at 1 and Uf years in the unrelated cases. 
t Includes six recipients of homografts from uncles (two), cousins (two), an aunt, and a niece. 
cases, there was no apparent consistent 
correlation between the NHR score and 
either the quality of renal function or the 
prednisone dose used to maintain this func-
tion (Table 1). For example, in the sibling 
cases at 2 years the best creatinine clear-
ances were in patients with the best NHR 
scores, but in the parental transplantations 
this correlation was inverse. Other examples 
of such incongruities are obvious in Table 1. 
Histopathology 
In sibling cases with an NHR ;?: 0.5, 
certain histopathologic changes were less 
common and less severe than with an NHR 
equal to 0.5. These included lesions affect-
ing the glomeruli, the tubules and the large 
and small arteries (Table 2). However, the 
eight siblings with very poor NHR's ( < .5) 
actually had significantly fewer glomerular 
lesions (categories 1 and 2, Table 2) and 
less fibrinogen than those with NHR's equal 
to 0.5. The demonstration of the latter in-
verse correlations (identified by enclosure 
in parentheses, Table 2) dealt a serious 
blow to the credibility of the positive corre-
lations in a subdivision of the same collec-
tion of sibling cases. In the parent to off-
spring transplantations, only 2 of the 13 
categories of histopathologic and immuno-
pathologic abnormalities were less if there 
was a high NHR (Table 2). 
In view of the foregoing findings, it was 
surprising in the unrelated cases to find a 
rather striking advantage of an NHR > .5 
in comparison to an NHR < .5. The former 
homo grafts were spared from structural 
damage to a statistically significant degree 
in eight of the nine categories defined by 
light and electron microscopy and in one of 
the 4 immunofluorescent columns (Table 
2). It was mentioned earlier under the sec-
tion on survival that an accidental bias 
could have been introduced by the circum-
stances of case selection and serologic 
analysis. 
DISCUSSION AND CONCLUSIONS 
The results underscore the need for con-
tinued evaluation of histocompatibility test-
ing employing different systems of analysis. 
Recently, these cases were examined using 
an alphabetical (A-D, F) method of pheno-
type match expression.2 A poor correlation 
of outcome with match was obtained except 
with siblings. The NHR's in the present 
study were calculated using the same sero-
logic raw data in an attempt to convert 
phenotypes into genotypes. An improved 
correlation was not obtained and in fact the 
discrimination within sibling cases was lost 
except when the NHR's were 0.88 or 
greater. Ten sibling recipients in the latter 
category (presumably double haplotype 
identity of HL-A chromosome) all lived for 
at least 31 months; the only kidney lost in 
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the group functioned for more than 5 years 
before failing. 
In order for decisive correlations to be 
obtained with any system of matching, it 
would be expected that incompatibilities 
would consistently cause failure and that 
uniform compatibilities would assure suc-
cess. Obviously, neither premise has been 
very completely fulfilled. Successful trans-
plantation has often been achieved despite 
frank antigenic mismatches. There have 
even been numerous instances of proven or 
probable multiple incompatibilities with an 
excellent result. For example, the four most 
badly matched sibling transplantations 
(NHR below .16) eventuated in perfect 
and continuing renal function after 38, 44, 
47, and 88 months. At 2-year biopsy, only 
one of these kidneys had significant struc-
tural abnormalities. It should also be noted 
that none of the major HL-A antigens pres-
ently detectable were neither uniquely haz-
ardous nor especially safe. 
HALGRIMSON ET A.L. 
In addition, it is necessary to explain 
failures despite apparently good HL-A 
matches. The presence of such cases in 
every large series means that other factors 
may significantly effect the results after 
renal transplantation. These could include 
other antigens within or outside the HL-A 
system, surgical technical considerations, 
and original host disease2 to mention only 
three. Consequently, while good HL-A 
matching should be a desirable condition 
in performing organ transplantation, the 
HL-A system may only be the tip of an 
enormous and as yet poorly understood 
biological iceberg. 
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